Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 5/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3694950 | 0.87 | SCD5 (0.46) | SCD5CNR1NPC1 | |
| SCHEMBL3689617 | 0.85 | SCD5 (0.40) | SCD5CNR1CHRM4NPC1KMT2A | |
| SCHEMBL3694774 | 0.85 | SCD5 (0.45) | SCD5CNR1 | |
| SCHEMBL3686135 | 0.84 | SCD5 (0.41) | SCD5PRCPCNR1ALDH1A1POLB | |
| SCHEMBL3698154 | 0.84 | SCD5 (0.42) | SCD5KMT2A | |
| SCHEMBL3691914 | 0.81 | SCD5 (0.44) | SCD5CNR1NPC1KMT2A | |
| SCHEMBL3688724 | 0.81 | SCD5 (0.41) | SCD5NPC1KMT2A | |
| SCHEMBL3692964 | 0.80 | SCD5 (0.48) | SCD5NPC1 | |
| SCHEMBL3691242 | 0.80 | SCD5 (0.48) | SCD5NPC1 | |
| SCHEMBL3691240 | 0.80 | SCD5 (0.48) | SCD5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| EP-2187883-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| WO-2009023179-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | OAT, HAVCR2, CPS1 | SCD5 2314/4885PRCP 1539/4885CNR1 524/4885 |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | OAT, HAVCR2, CPS1 | SCD5 2314/4885PRCP 1539/4885CNR1 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.